Chemotherapy-induced thrombocytopenia: shifting treatment strategies and the use of TPOR agonists

Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, comments on the current treatment landscape for patients with chemotherapy-induced thrombocytopenia (CIT). Dr Al-Samkari explains that, since the withdrawal of oprelvekin, no FDA- or EMA-approved agents have been available for the treatment of CIT. Dr Al-Samkari further discusses clinical trials and data on the off-label use of thrombopoietin receptor (TPOR) agonists such as romiplostim and avatrombopag, showing that these agents are safe and effective in this patient group. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.